Research programme: ocular therapeutics - Novaliq

Drug Profile

Research programme: ocular therapeutics - Novaliq

Alternative Names: Nov-03; Nov-04; Nov-05; Nov-07

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novaliq
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dry eyes; Glaucoma
  • Research Retinal disorders

Most Recent Events

  • 08 May 2017 Novaliq in collaboration with the University of Cologne intends to initiate a phase I trial in Dry eye in Germany
  • 13 Oct 2016 Research programme: ocular therapeutics - Novaliq is available for licensing as of 13 Oct 2016. http://www.novaliq.de/en/about-us/
  • 12 Oct 2016 Early research in Retinal disorders in Germany (unspecified route) (Novaliq pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top